secwatch / observer
8-K filed August 8, 2023, 7:59 PM ET ticker MTVA CIK 0001638287
regulatory confidence high sentiment negative materiality 0.60

MetaVia Inc. (MTVA): Nasdaq/NYSE listing notice — NeuroBo gets 180-day Nasdaq bid-price extension to Feb 5, 2024; still below $1.00

MetaVia Inc.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

MetaVia Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange
nasdaq
Notice
deficiency notice
Deficiency
minimum bid price
Rules
5550(a)(2), 5810(c)(3)(A)
Exact text from the filing
February 8, 2023, NeuroBo Pharmaceuticals, Inc. (the “Company” ) received a letter (the “Notice” ) from the Listing Qualifications Department (the “Staff” ) of the Nasdaq Stock Market ( “Nasdaq” ) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement” ). In accordance with Nasdaq Listing Rule
View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

MetaVia Inc. filing history →

Source: SEC EDGAR
accession 0001558370-23-013944
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.